Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 703 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreatic Cystic Fibrosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

NCT02776098
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

NCT00928135
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
12 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 29, 2026, 1:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Technology-enabled Patient Support System for Self-management of CF

NCT03910881
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Open-platform patient support system (PSS) app
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed No phase listed Observational

Orkambi Treatment in 2 to 5 Year Old Children With CF

NCT03795363
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Orkambi
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 5 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT03181932
View directory record Official record
Conditions
MRSA, Cystic Fibrosis
Interventions
Vancomycin inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
6 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 29, 2026, 1:59 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

NCT03669614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled AR-501, Inhaled Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

NCT02750501
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
Device · Other
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

NCT03537651
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia

NCT03734822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
End tidal CO2 (EtCO2), Transcutaneous CO2 (TCO2), Capillary CO2 (CapCO2), Arterial blood gas (ABG)
Other · Device · Diagnostic Test
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

NCT02951195
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-152, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed No phase listed Observational

Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs

NCT00590330
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 16 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis

NCT03020719
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Glutathione, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 29, 2026, 1:59 AM EDT
Active, not recruiting No phase listed Observational

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

NCT04206436
View directory record Official record
Conditions
Cystic Fibrosis, Bone Loss, Muscle Loss
Interventions
Cftr Modulators
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

MyVoice:CF Decision Aid for Women With Cystic Fibrosis

NCT04825236
View directory record Official record
Conditions
Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
Interventions
MyVoice:CF
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 29, 2026, 1:59 AM EDT
Withdrawn Not applicable Interventional

Thermic Effect of Feeding in Cystic Fibrosis

NCT03931252
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Boost VHC, Ensure High Protein
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

NCT00431964
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin 250 mg tablets, placebo tablets
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
6 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

NCT04183790
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

Repeatability and Response Study of Absorptive Clearance Scans

NCT01887197
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Absorptive clearance scan, inhaled hypertonic saline (7%), mannitol inhalation powder
Other · Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

NCT04853368
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 29, 2026, 1:59 AM EDT